Wechalekar, AD;
Chakraborty, R;
Lentzsch, S;
(2020)
Systemic Amyloidosis due to Low-Grade Lymphoma.
Hematology/Oncology Clinics of North America
, 34
(6)
pp. 1027-1039.
10.1016/j.hoc.2020.08.016.
Preview |
Text
Wechalekar_Systemic Amyloidosis due to Low-Grade Lymphoma_AAM.pdf - Accepted Version Download (488kB) | Preview |
Abstract
Lymphoma-related amyloidosis is a rare entity. Systemic AL amyloidosis is generally caused by an underlying plasma cell clone in the bone marrow with an intact monoclonal immunoglobulin G (IgG) or IgA protein. The rarity of the lymphoma-related amyloidosis makes the generation of data in randomized trials and the determination of the optimal treatment almost impossible. Therefore, treatment recommendations discussed here are based on either retrospective or small prospective trials of single centers.
| Type: | Article |
|---|---|
| Title: | Systemic Amyloidosis due to Low-Grade Lymphoma |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.hoc.2020.08.016 |
| Publisher version: | https://doi.org/10.1016/j.hoc.2020.08.016 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions. |
| Keywords: | IgM amyloidosis, Lymphoma-related AL amyloidosis, Rituximab, Waldenstrom macroglobulinemia |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10114979 |
Archive Staff Only
 |
View Item |
